🇺🇸 FDA

Intelligence · Clinical Pipeline

Anaxis Pharma Pipeline

All ClinicalTrials.gov programs at Anaxis Pharma — phase, modality, and trial IDs.

Programs
642

Quick answer

Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. CRD-4730, Encapsulation of microcrystalline cellulose into HPMC capsules to match the CRD-4730 active capsules in appearance

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

    phase 2 small molecule active

    1 trial

  2. CX11, Placebo to cx11 40 mg, CX11, Placebo to cx11 80 mg

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  3. Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory marginal zone lymphoma

    phase 2 small molecule active

    1 trial

  4. Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Waldenström Macroglobulinemia

    phase 2 small molecule active

    1 trial

  5. Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Richter's Syndrome, Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  6. Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. Calquence 100 mg hard capsules, IMBRUVICA 420 mg film-coated tablets, IMBRUVICA 140 mg hard capsules, IMBRUVICA 140 mg hard capsules, BRUKINSA 80 mg hard capsules, Lisaftoclax, Calquence 100 mg hard capsules, MabThera 500 mg concentrate for solution for infusion, Lisaftoclax, Lisaftoclax

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

    phase 2 small molecule active

    1 trial

  8. Cemiplimab and Fianlimab - 1, Fianlimab, Cemiplimab & Fianlimab - 2, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  9. Cemiplimab and Fianlimab - 1, Placebo, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, CARBOPLATIN, CISPLATIN, Cemiplimab & Fianlimab - 2, PACLITAXEL

    Lacuna Pharma Pty Ltd

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Chlorid sodný B. Braun 0,9 % infuzní roztok, DUOFAG

    Lacuna Pharma Pty Ltd

    Surgical wound infection/dehiscence caused by S. aureus and/or P. aeruginosa colonization

    phase 2 small molecule active

    1 trial

  11. Citanest® Dental Octapressin 30 mg/ml + 0,03 IE/ml, Xylocain ®Dental adrenalin 20 mg/ml + 12,5 mikrog/ml Injeksjonsvæske, oppløsning i sylindretter

    Lacuna Pharma Pty Ltd

    Subjects having local anesthesia for dental procedures.

    phase 2 small molecule active

    1 trial

  12. Cizutamig

    Lacuna Pharma Pty Ltd

    Severe, treatment refractory primary Sjögren’s disease (pSjD), Severe, treatment refractory idiopathic inflammatory myopathy (IIM), Severe, treatment refractory systemic sclerosis (SSc), Severe, treatment-refractory, seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA)

    phase 2 small molecule active

    1 trial

  13. Crofelemer Placebo Powder for Oral Solution

    Lacuna Pharma Pty Ltd

    Microvillous Inclusion Disease (MVID)

    phase 2 small molecule active

    1 trial

  14. DB-OTO

    Lacuna Pharma Pty Ltd

    Congenital Hearing Loss Secondary to Biallelic Pathogenic Variants of the Otoferlin Gene (OTOF)

    phase 2 small molecule active

    1 trial

  15. DCC-3014, DCC-3014, DCC-3014

    Lacuna Pharma Pty Ltd

    Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    phase 2 small molecule active

    1 trial

  16. DCC-3084, DCC-3084

    Lacuna Pharma Pty Ltd

    Solid tumors driven by the MAPK Pathway

    phase 2 small molecule active

    1 trial

  17. DNS-6288, DNS-6288

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia

    phase 2 small molecule active

    1 trial

  18. Dantrolene sodium semiheptahydrate, SODIUM CHLORIDE, VISTABEL 4 Allergan-Einheiten/0,1 ml Pulver zur Herstellung einer Injektionslösung, FTP-002/FTP-501 combination

    Lacuna Pharma Pty Ltd

    glabellar lines.

    phase 2 small molecule active

    1 trial

  19. Daridorexant matching placebo, QUVIVIQ 50 mg film-coated tablets, QUVIVIQ 25 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Insomnia Disorder

    phase 2 small molecule active

    1 trial

  20. Dexamethasone 4 mg tablets, Cytarabine 20 mg/ml Solution for Injection or Infusion, Calquence 100 mg hard capsules, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Histergan Tablets, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, Mesna Injection, Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Panadol 50

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  21. Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Paracetamol 500 mg Film-Coated Tablets, Diluent for REGN5458, Linvoseltamab, Diphenhydramine Hydrochloride 25 mg Tablets, Dermodrin 30 mg/2 ml soluție injectabilă, Dexamethasone 4 mg tablets, RoActemra 20 mg/mL concentrate for solution for infusion, Linvoseltamab

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  22. Diagnóstico prick Dermatophagoides farinae 40 HEP/ml, Diagnóstico prick control positivo, Diagnóstico prick Dermatophagoides pteronyssinus 40 HEP/ml, Diagnóstico prick control negativo

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  23. Diagnóstico prick control positivo, Diagnóstico prick Olea Europae, Diagnóstico prick control negativo, Diagnóstico prick Olea Europae, Diagnóstico prick Olea Europae, Diagnóstico prick Olea Europae

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  24. Diagnóstico prick control positivo, Dignostico prick Blomia tropicalis, Diagnóstico prick Blomia tropicalis, Diagnóstico prick Blomia tropicalis, Diagnóstico prick Blomia tropicalis, Diagnóstico prick control negativo

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  25. EP0062, ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  26. EPI-7386, Xtandi - 40 mg soft capsules

    Lacuna Pharma Pty Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  27. Emrusolmin

    Lacuna Pharma Pty Ltd

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  28. Evaluation of the safety and efficacy of Continuous Dopaminergic Stimulation by intracerebroventricular administration of anaerobically conserved dopamine in Parkinson's disease at the motor fluctuation stage: Single-center pilot study

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 other active

    1 trial

  29. Exenatide 3.5μg/mL solution for subcutaneous injection, Potassium canrenoate 5mg/mL solution for intravenous injection, Amodiaquine+Glibenclamide (10mg+0.1mg) /5mL oral suspension, Amodiaquine 2mg/mL solution for intravenous injection, Potassium canrenoate 25mg/5mL oral suspension

    Lacuna Pharma Pty Ltd

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial

  30. FLUOROURACIL , OXALIPLATIN , ABTL0812 Placebo, ABTL0812, IRINOTECAN , CALCIUM FOLINATE

    Lacuna Pharma Pty Ltd

    Metastatic pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  31. Fancalen

    Lacuna Pharma Pty Ltd

    Fanconi anemia (subtype A)

    phase 2 small molecule active

    1 trial

  32. G-STROPHANTHIN , The placebo vial contains NaCl 0.9% and phosphate buffer ad 1ml corresponding to the IMP except API for intravenous administration. There are no visible differences in comparison to volume, seize, exterior, colour etc. of the investigational product.

    Lacuna Pharma Pty Ltd

    Acute Heart Failure

    phase 2 small molecule active

    1 trial

  33. GL0034 4 mg/ml, 1 ml per vial, GL0034 3 mg/ml, 1 ml per vial, Same solution as for GL0034 without drug substance; solution for subcutaneous injection; volume identical to dose of test product, GL0034 1mg/ml, 0.6ml per vial, GL0034 1 mg/ml, 1 ml per vial

    Lacuna Pharma Pty Ltd

    Type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  34. GR1014 Cutaneous Gel, The placebo ingredients are identical to those of GR1014-CG with the exception that the drug substance (amifostine) and hydrochloric acid (used at the hydrolysis step to convert amifostine in the active substance, amifostine thiol) are omitted.

    Lacuna Pharma Pty Ltd

    Radiation-induced dermatitis (radiodermatitis)

    phase 2 small molecule active

    1 trial

  35. GTX-102, GTX/UX Diluent and Flush Solution

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 2 small molecule active

    1 trial

  36. Galvokimig, Placebo matching Test 0.9% sodium chloride solution for injection

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  37. HDP-101

    Lacuna Pharma Pty Ltd

    Relapsed or refractory Multiple Myeloma (r/r MM)

    phase 2 small molecule active

    1 trial

  38. HarMono-T 5 microlitres/mL gas and solvent for dispersion for injection/infusion

    Lacuna Pharma Pty Ltd

    Ultrasound contrast agent, for diagnostic purposes (to assess indeterminate kidney lesions)

    phase 2 small molecule active

    1 trial

  39. Humanized immunoglobulin G1 (IgG1) kappa monoclonal antibody (mAb) targeting PAUF

    Lacuna Pharma Pty Ltd

    Advanced and/or metastatic pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  40. IDOR-1117-2520 matching placebo

    Lacuna Pharma Pty Ltd

    Moderate to severe chronic plaque psoriasis

    phase 2 small molecule active

    1 trial

  41. IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., PEMETREXED , PACLITAXEL , IMFINZI 50 mg/mL concentrate for solution for infusion., IPH5201, CISPLATIN

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer II, III

    phase 2 small molecule active

    1 trial

  42. INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) Deficiency, Generalized Arterial Calcification of Infancy (GACI), Pseudoxanthoma elasticum (PXE)

    phase 2 small molecule active

    1 trial

  43. IPH6501

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  44. IRINOTECAN, lurbinectedin

    Lacuna Pharma Pty Ltd

    Selected Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  45. Ilofotase alfa, Ilofotase alfa Placebo Drug Product

    Lacuna Pharma Pty Ltd

    Risk for renal damage following open heart surgery

    phase 2 small molecule active

    1 trial

  46. Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection in pre-filled syringe, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, REGN7508

    Lacuna Pharma Pty Ltd

    Thromboembolic disease

    phase 2 small molecule active

    1 trial

  47. JAB-21822

    Lacuna Pharma Pty Ltd

    advanced solid tumors with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  48. JTT-861, Placebo tablet for JTT-861

    Lacuna Pharma Pty Ltd

    Heart Failure (Heart Failure with Reduced Ejection Fraction)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Anaxis Pharma have?

642 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.